Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an announcement.
Genflow Biosciences Plc announced the publication of its second European patent application for a SIRT6 gene variant targeting non-alcoholic steatohepatitis (NASH), marking a significant milestone in its intellectual property portfolio. This development strengthens Genflow’s IP leadership in the longevity and metabolic disease space, establishing a robust European patent framework that supports its therapeutic platform and future clinical programs, thereby enhancing partnership potential and long-term value creation.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on pioneering gene therapies to decelerate the aging process. The company aims to promote longer and healthier lives and mitigate the impacts of an aging global population. Its lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, with ongoing clinical trials in aged dogs and plans for trials in treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 7,913,645
Technical Sentiment Signal: Buy
See more insights into GENF stock on TipRanks’ Stock Analysis page.